Health Condition 1: A811- Subacute sclerosing panencephalitis
Conditions
Interventions
Intervention1: Amantadine: oral amantadine tablet at a dose of 5 mg/kg/day in two divided doses daily for 12 weeks, along with oral isoprinosine tablets 100 mg/kg/day daily in three divided doses for
Sponsors
All India institute of medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Children aged less then 18 years with diagnosis of SSPE according to modified Dykens criteria 2.Parents willing to comply with the study protocol and followup
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA 1.Preexisting renal impairment 2.Caregivers not giving informed consent 3.History of allergy to amantadine previously
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in SSPE severity score at 12 weeks as compared to the baseline.Timepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in Neurological Disability Index (NDI) 2. Change in functional status (measured by WeeFIM) 3. Change in social quotient (measured by VSMS) 4. Frequency of daily convulsive seizures 5. Severity of myoclonus (measured by UMRS) 6. EEG abnormalities 7. Survival rate Timepoint: 12 WEEKS | — |
Countries
India
Contacts
Public ContactDr Indar Kumar Sharawat
AIIMS Rishikesh
Outcome results
None listed